35 related articles for article (PubMed ID: 17227498)
1. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.
Forgue ST; Phillips DL; Bedding AW; Payne CD; Jewell H; Patterson BE; Wrishko RE; Mitchell MI
Br J Clin Pharmacol; 2007 Jan; 63(1):24-35. PubMed ID: 16869816
[TBL] [Abstract][Full Text] [Related]
2. Tadalafil pharmacokinetics in healthy subjects.
Forgue ST; Patterson BE; Bedding AW; Payne CD; Phillips DL; Wrishko RE; Mitchell MI
Br J Clin Pharmacol; 2006 Mar; 61(3):280-8. PubMed ID: 16487221
[TBL] [Abstract][Full Text] [Related]
3. Erectile dysfunction after therapy with metoprolol: the Hawthorne effect.
Cocco G
Cardiology; 2009; 112(3):174-7. PubMed ID: 18654082
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries.
Mirone V; Costa P; Damber JE; Holmes S; Moncada I; Van Ahlen H; Wespes E; Cordell WH; Chan M; Lembo D; Varanese L
Eur Urol; 2005 Jun; 47(6):846-54; discussion 854. PubMed ID: 15925082
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy.
Mirone V; Imbimbo C; Rossi A; Sicuteri R; Valle D; Longo N; Fusco F;
Asian J Androl; 2007 May; 9(3):395-402. PubMed ID: 17486281
[TBL] [Abstract][Full Text] [Related]
6. Time from dosing to sexual intercourse attempts in men taking tadalafil in clinical trials.
Shabsigh R; Burnett AL; Eardley I; Sharlip ID; Ellsworth PI; Garcia CS; Natanegara F; Ahuja S
BJU Int; 2005 Oct; 96(6):857-63. PubMed ID: 16153217
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
[TBL] [Abstract][Full Text] [Related]
8. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.
Young JM; Feldman RA; Auerbach SM; Kaufman JM; Garcia CS; Shen W; Murphy AM; Beasley CM; Hague JA; Ahuja S
J Androl; 2005; 26(3):310-8. PubMed ID: 15866997
[TBL] [Abstract][Full Text] [Related]
9. The influence of age on treatment outcomes in men with erectile dysfunction treated with two regimens of tadalafil: results of the SURE study.
Wespes E; Moncada I; Schmitt H; Jungwirth A; Chan M; Varanese L
BJU Int; 2007 Jan; 99(1):121-6. PubMed ID: 17227498
[TBL] [Abstract][Full Text] [Related]
10. A new era in the treatment of erectile dysfunction: chronic phosphodiesterase type 5 inhibition.
Fusco F; Razzoli E; Imbimbo C; Rossi A; Verze P; Mirone V
BJU Int; 2010 Jun; 105(12):1634-9. PubMed ID: 20553468
[TBL] [Abstract][Full Text] [Related]
11. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily.
Porst H; Hell-Momeni K; Büttner H
Expert Opin Pharmacother; 2012 Jul; 13(10):1481-94. PubMed ID: 22725705
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of tadalafil for the treatment of erectile dysfunction].
Liu ZY; Sun YH
Zhonghua Nan Ke Xue; 2008 Apr; 14(4):377-80. PubMed ID: 18481436
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
